Valziflocept - Shire

Drug Profile

Valziflocept - Shire

Alternative Names: BAX 1810; FcγRIIb; Human soluble Fc-gamma receptor IIb - Shire; SHP 652; SM-101

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SuppreMol
  • Developer Baxalta; Shire
  • Class Immunoglobulin Fc fragments; Recombinant proteins
  • Mechanism of Action Fc gamma receptor IIB modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Systemic lupus erythematosus
  • Discontinued Chronic obstructive pulmonary disease; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 01 Jul 2018 Discontinued - Phase-II for Idiopathic thrombocytopenic purpura in Russia, Ukraine, Belgium, Poland, Germany (IV) (Shire pipeline, July 2018)
  • 01 Jul 2018 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Germany (Parenteral) (Shire pipeline, July 2018)
  • 28 Feb 2018 Clinical hold for Systemic lupus erythematosus in Netherlands, Poland, United Kingdom, Spain, Italy, France, Czech Republic, Belgium, Australia, Germany (IV) (Shire pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top